Cuenca

Researchers are collecting detailed information about patients with venous thromboembolism (VTE), which includes blood clots in veins such as deep-vein thrombosis and pulmonary embolism. The project aims to improve doctors' understanding of VTE, especially in patients often excluded from clinical trials, like pregnant women, elderly individuals, cancer patients, and those with other complex health issues. The goal is to reduce deaths, clot recurrence, bleeding problems, and artery-related events by sharing this knowledge widely. The study involves gathering extensive data on each patient's health status, treatments, and outcomes during the first three months of therapy. This registry is available online to help doctors quickly find information on patients with similar medical profiles and make informed decisions about managing high-risk individuals. There are no specific interventions being tested; instead, the focus is on collecting real-world patient data. Participants provide informed consent and are followed for at least three years to monitor for new clot events and complications. Researchers track recurrences of VTE, bleeding episodes, and deaths, aiming to create tools that predict which patients are most at risk for problems. This ongoing data collection supports improving care and guiding treatment decisions for diverse patient groups over time.

Researchers are working to develop and validate a model that predicts the risk of acquiring sexually transmitted infections (STIs) among people using HIV pre-exposure prophylaxis (PrEP) within Spain's national program. This study includes individuals who use PrEP, following them across multiple hospitals in Spain to understand factors associated with STI acquisition. The study focuses on various STIs including syphilis, gonorrhea, chlamydia, herpes, hepatitis, HIV infection, and MPOX. Participants will be followed quarterly according to national protocols. At each visit, samples will be collected from different sites such as blood, throat, urine, rectum, genital areas, and ulcers to diagnose STIs. There is no intervention, as this is an observational cohort study. The main goal is to track if participants develop an STI and to count the number of diagnosed STIs over time. Statistical models will be used to analyze the data and validate the best predictive models. During the study, participants will have regular follow-up visits every three months where medical evaluations and STI testing will be performed. Researchers will use the collected data to create and validate a predictive model for STI risk over an average of five years. The study does not exclude any participants based on specific criteria, and all individuals who have started oral PrEP and meet the national guidelines are eligible to take part.

Researchers are investigating the effects of different doses of dexamethasone, a corticosteroid, in adults with acute hypoxemic respiratory failure (AHRF) caused by infections, including COVID-19. This condition ranges from mild respiratory illness to severe pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure, and death. The trial aims to clarify whether moderate doses of dexamethasone reduce mortality more than low doses in patients requiring mechanical ventilation in intensive care units. Participants will be randomly assigned to receive intravenous dexamethasone either at a low dose of 6 mg per day for 10 days or a higher dose regimen of 20 mg per day for 5 days followed by 10 mg per day for another 5 days. This is a randomized, controlled, open-label study conducted across multiple centers in Spain. The study focuses on patients who are mechanically ventilated with confirmed pulmonary or systemic infections causing AHRF or ARDS. During the study, researchers will monitor patients for 60-day mortality as the main outcome and assess the number of days they are free from mechanical ventilation within 28 days. The study follows the intention-to-treat principle, ensuring all randomized patients are analyzed according to their assigned treatment. The trial includes detailed clinical assessments, chest imaging, and oxygenation measurements as part of patient evaluation throughout the treatment period.

Nuts are known for their rich nutrients and have been linked to heart and metabolic health benefits. Observational studies suggest that eating nuts might improve mental health, including lowering depression risk and enhancing mood, but experimental evidence is still limited. This trial focuses on young adults aged 18 to 24, a key period for mental health changes, to explore how eating nuts affects mental health symptoms, thinking skills, sleep, well-being, and brain-related biochemical markers. Participants will be divided into three groups: one group will eat 30 grams of mixed nuts daily, another will consume 60 grams daily, and a control group will continue their usual diet without added nuts. Nuts will be provided free for six months, and participants can eat them in any preferred way. After the six-month period, participants will resume their normal diet, and a final session will be held six months later to collect data at the 12-month mark. Throughout the study, researchers will assess depression, anxiety, stress, memory, thinking skills like working memory and cognitive flexibility, attention, processing speed, and levels of Brain Derived Neurotrophic Factor at the start, 3, 6, and 12 months. Participants will also have their sleep quality, overall well-being, and quality of life evaluated to understand how nut consumption influences various aspects of mental and brain health over time.

Out-of-hospital cardiorespiratory arrest (OHCA) is a serious health issue with high rates of illness and death, significantly impacting individuals and society. To help increase the number of people who can respond effectively to OHCA by performing basic life support (BLS), the European Resuscitation Council recommends training schoolchildren in cardiopulmonary resuscitation (CPR) through initiatives like "Kids Save Lives." This trial aims to evaluate how well two different CPR teaching methods improve both theoretical knowledge and practical skills in children aged 5 to 13 years. The study compares two teaching approaches: Intervention Group 1 (IG1) receives a 2-hour session combining theory and hands-on practice using mannequins, led by nursing professionals with a ratio of one instructor per 25 students and one mannequin per 2-3 students. Intervention Group 2 (IG2) watches a short video (5-10 minutes) and uses a puzzle as teaching tools without any mannequin practice, with one video per 25 students and one puzzle per student. Both methods are designed to teach BLS sequences and CPR skills to schoolchildren enrolled in primary education. Participants will be assessed on their theoretical CPR knowledge before and immediately after the intervention, as well as at an 8-month follow-up. Practical CPR skills and the quality of CPR are also measured immediately after the session and at follow-up. The study collects data on how these teaching methods affect knowledge retention and skill performance, considering factors such as age, physical condition, and sociodemographic characteristics. Parents or guardians must consent for their children to join, and the total participation includes initial training and follow-up assessments.

Researchers are conducting a multicenter cohort study to collect long-term information from female patients diagnosed with early-stage invasive breast cancer. These patients were previously included in neoadjuvant or adjuvant clinical trials conducted by the GEICAM group. The study aims to describe the long-term evolution and outcomes of these patients over approximately 30 years of follow-up, providing valuable data on treatment effects and any late-occurring consequences beyond initial analyses. The study involves patients who completed follow-up from their original neoadjuvant or adjuvant GEICAM clinical trials starting from 1998. Participants will be observed for up to 30 years to thoroughly assess event-free survival in neoadjuvant studies and disease-free survival in adjuvant studies. This extended monitoring period allows researchers to evaluate the long-term efficacy and safety of treatments received during those trials. Throughout the study, participants' health status will be regularly assessed to monitor survival outcomes and any disease recurrence. Information such as survival without events and disease-free survival will be collected and tracked across the entire follow-up period. The long-term data gathered will support healthcare professionals, patients, and society in understanding breast cancer progression and the lasting impact of treatments over decades.

Researchers are conducting an observational study called SOGUG-PRINCIS to collect and analyze data on the effectiveness of drugs recently approved for treating genitourinary tumors under routine clinical practice in Spain. This national, multicenter study includes both retrospective patient data and prospective follow-up, aiming to validate real-world outcomes compared to those reported in phase III clinical trials. The study covers cancers originating in the kidney, ureter, bladder, prostate, testicle, urethra, penis, and seminal vesicles. The study observes patients treated with drugs such as darolutamide combined with androgen deprivation therapy and docetaxel, adjuvant nivolumab after surgical removal of urothelial carcinoma, and enfortumab vedotin. All treatments follow their approved dosing and administration guidelines in standard clinical practice. New subprojects may be added as new drugs gain funding approval by the Spanish National Health System, with each subproject focusing on specific primary endpoints. Participants' involvement includes treatment decisions made independently from the study, with data collected afterward to assess outcomes. Researchers will track progression-free survival at 18 months, relapse-free survival at 24 months, and overall survival at 12 months after treatment initiation. The study also serves as a registry for genitourinary cancer treatments funded nationally, supporting long-term evaluation of drug effectiveness in real-world settings.

Researchers are studying patients diagnosed with cancer who experience a venous or arterial thromboembolic event, either symptomatic or found incidentally. These events may occur within a month before the cancer diagnosis or at any time after it. This observational, epidemiological, multicenter study aims to gather detailed data about these thromboembolic episodes in cancer patients. The study does not involve any interventions or treatments but collects information about the thromboembolic event, including its location, vessel of origin, diagnosis type, and characteristics of cancer at the time of the event. It also records the timing between cancer diagnosis and the thromboembolism. Participants are observed over time, with data collected at baseline and a 12-month follow-up visit to assess patient status and treatment details. Participants provide consent and undergo imaging confirmation of thromboembolic events using techniques like Doppler echocardiography or CT angiography. Researchers track multiple outcome measures such as tumor classification, primary tumor presence, and treatment administered for cancer. The study monitors participants for a year to record their clinical situation and gather comprehensive information on cancer-associated thrombosis.

This observational, multicenter study focuses on patients diagnosed with lung cancer and other thoracic tumors. It aims to improve treatment and prognosis by exploring patient data related to the expression of markers that predict responses to chemotherapy and molecular inhibitors. The study reflects a commitment to individualized treatment and understanding the epidemiology of thoracic tumors in Spain, addressing the high mortality and variability in diagnosis and treatment. The study collects information both retrospectively and prospectively from clinical histories of patients treated by thoracic surgeons and medical oncologists. It investigates epidemiological and therapeutic factors associated with thoracic tumors, including lung cancer, to support strategies like multidisciplinary care and early diagnosis. There are no interventions or treatments assigned, as this is an observational registry gathering comprehensive real-world data. Participants will have their clinical data reviewed to describe characteristics of lung cancer and other thoracic tumors over up to 10 years. The study aims to explore the epidemiology and treatment approaches, supporting future improvements in care. There is no age or gender restriction, and data collection includes both patients receiving active treatment and those under palliative care. The study duration, follow-up, and specific assessments are based on patient records and available medical information.

Researchers are evaluating how anxiety and depression symptoms change over time in adults diagnosed with solid cancers. The study aims to identify factors that might predict these symptom patterns, including sociodemographic traits like age and marital status, clinical details such as tumor location and treatment type, psychological aspects like coping methods and fear of recurrence, as well as levels of physical activity. It also explores how these factors relate to patients' needs for support and the use of psychosocial care services. Participants undergo psychosocial and clinical assessments at three points: at diagnosis or start of treatment, and at 3 and 6 months afterward. These assessments include standardized questionnaires covering psychological symptoms, quality of life, cognitive difficulties, physical activity, nutrition, and support needs. Medical records are reviewed to gather clinical information. There is no experimental treatment involved in the study. Throughout the study, participants provide information through self-report questionnaires, allowing researchers to track changes in anxiety and depression symptoms and other factors over time. The main outcomes focus on symptom levels at diagnosis, and their early and medium-term changes at 3 and 6 months. The study involves adults with confirmed solid cancers who are starting systemic antineoplastic treatment or have advanced disease, with total participation lasting at least 6 months.